NYSE:BXLT - Baxalta Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$46.02 -0.18 (-0.39 %)
(As of 05/21/2018 02:32 PM ET)
Previous Close$46.20
Today's Range$46.01 - $46.52
52-Week Range$29.83 - $46.52
Volume228.65 million shs
Average Volume12.66 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend Yield0.61%
BetaN/A

About Baxalta (NYSE:BXLT)

Baxalta logoBaxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive BXLT News and Ratings via Email

Sign-up to receive the latest news and ratings for BXLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNYSE:BXLT
CUSIPN/A
Phone+1-224-9402000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins9.37%
Return on Equity14.28%
Return on Assets4.62%

Miscellaneous

EmployeesN/A
Outstanding Shares683,080,000

Baxalta (NYSE:BXLT) Frequently Asked Questions

What is Baxalta's stock symbol?

Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."

How were Baxalta's earnings last quarter?

Baxalta Inc (NYSE:BXLT) released its earnings results on Thursday, April, 28th. The biotechnology company reported $0.47 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.46 by $0.01. The biotechnology company earned $1.50 billion during the quarter, compared to the consensus estimate of $1.47 billion. Baxalta had a return on equity of 14.28% and a net margin of 9.37%. Baxalta's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS. View Baxalta's Earnings History.

Has Baxalta been receiving favorable news coverage?

Press coverage about BXLT stock has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Baxalta earned a news impact score of 0.01 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.12 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Baxalta?

Shares of BXLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Baxalta's stock price today?

One share of BXLT stock can currently be purchased for approximately $46.02.

How can I contact Baxalta?

Baxalta's mailing address is 1200 Lakeside Dr, BANNOCKBURN, IL 60015-1243, United States. The biotechnology company can be reached via phone at +1-224-9402000.


MarketBeat Community Rating for Baxalta (BXLT)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  95 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  182
MarketBeat's community ratings are surveys of what our community members think about Baxalta and other stocks. Vote "Outperform" if you believe BXLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BXLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Baxalta (NYSE:BXLT) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 5/21/2016 forward)

Earnings

Baxalta (NYSE:BXLT) Earnings History and Estimates Chart

Earnings by Quarter for Baxalta (NYSE:BXLT)

Baxalta (NYSE BXLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/28/2016Q116$0.46$0.47$1.47 billion$1.50 billionViewN/AView Earnings Details
2/16/2016Q415$0.56$0.57$1.71 billion$1.80 billionViewN/AView Earnings Details
10/29/2015Q315$0.49$0.56$1.51 billion$1.60 billionViewListenView Earnings Details
7/30/2015Q215$0.50$0.40$1.41 billion$1.47 billionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Baxalta (NYSE:BXLT) Dividend Information

Baxalta pays an annual dividend of $0.28 per share, with a dividend yield of 0.61%. BXLT's most recent quarterly dividend payment was Friday, July 1.
Most Recent Dividend:7/1/2016
Annual Dividend:$0.28
Dividend Yield:0.61%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio(s):N/A
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Baxalta (NYSE:BXLT)

Baxalta (NYSE:BXLT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/10/2016Quarterly$0.076/8/20166/10/20167/1/2016
5/10/2016quarterly$0.070.66%6/8/20166/10/20167/1/2016
2/24/2016quarterly$0.070.72%3/8/20163/10/20164/1/2016
11/18/2015quarterly$0.070.81%12/2/201512/4/20151/4/2016
7/28/2015quarterly$0.079/2/20159/4/201510/1/2015
(Data available from 1/1/2013 forward)

Insider Trades

Baxalta (NYSE BXLT) Insider Trading and Institutional Ownership History

Insider Trading History for Baxalta (NYSE:BXLT)
Insider Trading History for Baxalta (NYSE:BXLT)

Baxalta (NYSE BXLT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/24/2016Albert P L StrouckenDirectorSell5,660$39.98$226,286.8026,415View SEC Filing  
2/25/2016Blake E DevittDirectorBuy5,900$39.17$231,103.0027,965View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Baxalta (NYSE BXLT) News Headlines

Source:
DateHeadline
Financial Comparison: Baxalta (BXLT) and Vitae Pharmaceuticals (VTAE)Financial Comparison: Baxalta (BXLT) and Vitae Pharmaceuticals (VTAE)
www.americanbankingnews.com - March 30 at 5:21 AM
Head to Head Survey: Baxalta (BXLT) vs. Auxilium Pharmaceuticals (AUXL)Head to Head Survey: Baxalta (BXLT) vs. Auxilium Pharmaceuticals (AUXL)
www.americanbankingnews.com - March 21 at 7:20 PM
Shire Acq Inv Ireland Designated Activity Co -- Moodys affirms Shire at Baa3; revises outlook to positiveShire Acq Inv Ireland Designated Activity Co -- Moody's affirms Shire at Baa3; revises outlook to positive
finance.yahoo.com - March 20 at 4:19 PM
Head to Head Analysis: Opiant Pharmaceuticals (OPNT) vs. Baxalta (BXLT)Head to Head Analysis: Opiant Pharmaceuticals (OPNT) vs. Baxalta (BXLT)
www.americanbankingnews.com - March 15 at 9:16 PM
Analyzing Baxalta (BXLT) and Mediwound (MDWD)Analyzing Baxalta (BXLT) and Mediwound (MDWD)
www.americanbankingnews.com - January 31 at 11:12 PM
Financial Survey: Horizon Therapeutics (HPTX) versus Baxalta (BXLT)Financial Survey: Horizon Therapeutics (HPTX) versus Baxalta (BXLT)
www.americanbankingnews.com - January 31 at 7:12 PM
Head-To-Head Analysis: Baxalta (BXLT) versus Its RivalsHead-To-Head Analysis: Baxalta (BXLT) versus Its Rivals
www.americanbankingnews.com - January 25 at 1:24 AM
Head to Head Comparison: Baxalta (BXLT) & The CompetitionHead to Head Comparison: Baxalta (BXLT) & The Competition
www.americanbankingnews.com - January 24 at 9:16 AM
Head-To-Head Analysis: Baxalta (BXLT) & Its PeersHead-To-Head Analysis: Baxalta (BXLT) & Its Peers
www.americanbankingnews.com - January 23 at 5:06 AM
Head-To-Head Survey: Baxalta (BXLT) vs. Its PeersHead-To-Head Survey: Baxalta (BXLT) vs. Its Peers
www.americanbankingnews.com - January 18 at 7:48 PM
Head-To-Head Review: Baxalta (BXLT) & Argos Therapeutics (ARGS)Head-To-Head Review: Baxalta (BXLT) & Argos Therapeutics (ARGS)
www.americanbankingnews.com - January 18 at 7:14 AM
Baxalta (BXLT) & Its Peers Head-To-Head SurveyBaxalta (BXLT) & Its Peers Head-To-Head Survey
www.americanbankingnews.com - January 16 at 9:32 AM
3SBio (SSRX) and Baxalta (BXLT) Head-To-Head Analysis3SBio (SSRX) and Baxalta (BXLT) Head-To-Head Analysis
www.americanbankingnews.com - January 16 at 1:10 AM
Baxalta (BXLT) & The Competition Critical ComparisonBaxalta (BXLT) & The Competition Critical Comparison
www.americanbankingnews.com - January 11 at 5:24 PM
Analyzing Baxalta (BXLT) and The CompetitionAnalyzing Baxalta (BXLT) and The Competition
www.americanbankingnews.com - January 9 at 9:38 AM
Baxalta (BXLT) and Syros Pharmaceuticals (SYRS) Head-To-Head AnalysisBaxalta (BXLT) and Syros Pharmaceuticals (SYRS) Head-To-Head Analysis
www.americanbankingnews.com - January 8 at 10:02 PM
Analyzing Baxalta (BXLT) and Its CompetitorsAnalyzing Baxalta (BXLT) and Its Competitors
www.americanbankingnews.com - January 6 at 7:14 PM
Sonoma Pharmaceuticals (SNOA) vs. Baxalta (BXLT) Head to Head AnalysisSonoma Pharmaceuticals (SNOA) vs. Baxalta (BXLT) Head to Head Analysis
www.americanbankingnews.com - January 6 at 5:12 PM
Baxalta (BXLT) & Its Competitors Critical ComparisonBaxalta (BXLT) & Its Competitors Critical Comparison
www.americanbankingnews.com - January 6 at 1:10 AM
Head to Head Review: Baxalta (BXLT) & Its CompetitorsHead to Head Review: Baxalta (BXLT) & Its Competitors
www.americanbankingnews.com - January 4 at 9:56 AM
Baxalta (BXLT) & The Competition Head to Head ContrastBaxalta (BXLT) & The Competition Head to Head Contrast
www.americanbankingnews.com - January 3 at 8:12 AM
Comparing Baxalta (BXLT) & Its RivalsComparing Baxalta (BXLT) & Its Rivals
www.americanbankingnews.com - December 30 at 7:50 AM
Comparing Baxalta (BXLT) and Its CompetitorsComparing Baxalta (BXLT) and Its Competitors
www.americanbankingnews.com - December 29 at 9:30 PM
Financial Survey: Baxalta (BXLT) versus The CompetitionFinancial Survey: Baxalta (BXLT) versus The Competition
www.americanbankingnews.com - December 26 at 5:24 PM
Fortress Biotech (FBIO) vs. Baxalta (BXLT) Head to Head ContrastFortress Biotech (FBIO) vs. Baxalta (BXLT) Head to Head Contrast
www.americanbankingnews.com - November 15 at 7:14 AM
How Does Baxter Create Value for Its Shareholders?How Does Baxter Create Value for Its Shareholders?
finance.yahoo.com - October 5 at 12:00 PM
5 Companies Reach 52-Week Highs5 Companies Reach 52-Week Highs
finance.yahoo.com - October 5 at 12:00 PM
Durham company bulks up executive suite as cancer therapy development moves forwardDurham company bulks up executive suite as cancer therapy development moves forward
finance.yahoo.com - July 13 at 5:53 PM
Julian Robertson Buys Adobe and Sells Apple in 1st Quarter - NasdaqJulian Robertson Buys Adobe and Sells Apple in 1st Quarter - Nasdaq
www.nasdaq.com - May 16 at 4:10 PM
Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout SpeculationTakeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation
www.thestreet.com - January 9 at 5:14 PM
CTI Biopharma stock revived after FDA ruling, reverse stock splitCTI Biopharma stock revived after FDA ruling, reverse stock split
www.bizjournals.com - January 6 at 9:27 PM
Shire reiterates full-year guidance after in-line Q3Shire reiterates full-year guidance after in-line Q3
uk.finance.yahoo.com - November 1 at 4:02 PM
Houston cancer company closes additional funding - Houston Business JournalHouston cancer company closes additional funding - Houston Business Journal
www.bizjournals.com - October 10 at 3:54 PM
Shire plc -- Moodys assigns Baa3 to Shires sr. notes; stable outlookShire plc -- Moody's assigns Baa3 to Shire's sr. notes; stable outlook
www.moodys.com - September 16 at 3:56 PM
Tracking Stephen Mandels Lone Pine Capital Portfolio - Q2 2016 Update - Seeking AlphaTracking Stephen Mandel's Lone Pine Capital Portfolio - Q2 2016 Update - Seeking Alpha
seekingalpha.com - August 25 at 4:05 PM
Form N-PX WELLS FARGO FUNDS TRUST For: Jun 30 - StreetInsider.comForm N-PX WELLS FARGO FUNDS TRUST For: Jun 30 - StreetInsider.com
www.streetinsider.com - August 25 at 8:54 AM
Tracking Tweedy Browne Portfolio - Q2 2016 Update - Seeking AlphaTracking Tweedy Browne Portfolio - Q2 2016 Update - Seeking Alpha
seekingalpha.com - August 12 at 12:40 PM
Baxter International Inc. -- Moodys rates Baxters new notes Baa2; outlook stableBaxter International Inc. -- Moody's rates Baxter's new notes Baa2; outlook stable
www.moodys.com - August 10 at 3:28 PM
Apple-Twitter: Why Not? - Seeking AlphaApple-Twitter: Why Not? - Seeking Alpha
seekingalpha.com - August 7 at 3:59 PM
Shire Says Baxalta Combination to Boost Profit and SalesShire Says Baxalta Combination to Boost Profit and Sales
www.bloomberg.com - August 2 at 8:51 AM
Shire upgrades Baxalta cost savings after Q2 earnings beatShire upgrades Baxalta cost savings after Q2 earnings beat
uk.finance.yahoo.com - August 2 at 8:51 AM
Shire lifts earnings and Baxalta cost saving targetsShire lifts earnings and Baxalta cost saving targets
uk.finance.yahoo.com - August 2 at 8:51 AM
[$$] Shire Earnings: What to Watch[$$] Shire Earnings: What to Watch
www.wsj.com - August 1 at 4:00 PM
3 Mutual Funds Focusing on Arbitrage Profits (MERFX, ARBFX)3 Mutual Funds Focusing on Arbitrage Profits (MERFX, ARBFX)
www.investopedia.com - July 28 at 10:00 AM
Dan Loebs Third Point tells why investing is like Game of ThronesDan Loeb's Third Point tells why investing is like 'Game of Thrones'
www.cnbc.com - July 26 at 8:26 PM
Baxter Beats Earnings Estimates, Raises Full-Year GuidanceBaxter Beats Earnings Estimates, Raises Full-Year Guidance
www.bloomberg.com - July 26 at 7:11 AM
Tweedy Browne Global Value Fund Makes Trades Around the World - NasdaqTweedy Browne Global Value Fund Makes Trades Around the World - Nasdaq
www.nasdaq.com - July 13 at 3:59 PM
Biotech ETF IBB Short Squeeze May Be Ahead - Seeking AlphaBiotech ETF IBB Short Squeeze May Be Ahead - Seeking Alpha
seekingalpha.com - July 12 at 4:05 PM
Top 3 Stocks Hedge Funds Bought in Q1, 2016Top 3 Stocks Hedge Funds Bought in Q1, 2016
www.investopedia.com - June 21 at 10:00 AM
Top 3 Stocks Hedge Funds Bought in Q1, 2016Top 3 Stocks Hedge Funds Bought in Q1, 2016
www.investopedia.com - June 21 at 10:00 AM

SEC Filings

Baxalta (NYSE:BXLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Baxalta (NYSE:BXLT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Baxalta (NYSE BXLT) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.